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Corey Cutler,1 Haesook T. Kim,2 Shake Ayanian,3 Gary Bradwin,3 Carolyn Revta,1
Julie Aldridge,2 Vincent Ho,1 Edwin Alyea,1 John Koreth,1 Philippe Armand,1 Robert Soiffer,1
Jerome Ritz,1 Paul G. Richardson,1 Joseph H. Antin1Predicting the development of veno-occlusive disease (VOD) of the liver remains challenging. We hypothe-
sized that biomarkers of endothelial injury in myeloablative allogeneic transplantation recipients could
predict VOD occurrence. We evaluated 4 biomarkers—von Willebrand Factor (vWF), thrombomodulin,
E-selectin, and soluble intercellular adhesion molecule-1 (sICAM-1)—weekly in the peritransplantation
period in an attempt to predict VOD. In the patients who received sirolimus, vWF, thrombomodulin,
and sICAM-1 levels were significantly elevated in patients with VOD compared with those without
VOD on day 21 (P # .035), day 17 (P # .0001), and day 114 (P # .004). E-selectin was predictive on day
17 (P 5 .007). Levels of vWF $1400 IU/mL and thrombomodulin $100 ng/mL on day 17 were both
100% sensitive and 100% specific in predicting VOD. These biomarkers were informative when adjusted
for other risk factors for VOD in regression analysis. Among patients not receiving sirolimus, biomarkers
of endothelial injury were not informative. We conclude that vWF, thrombomodulin, and sICAM-1 eleva-
tions before and early after transplantation may be useful in predicting VOD in patients receiving sirolimus.
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Veno-occlusive disease (VOD, also referred to as
sinusoidal obstruction syndrome) of the liver occurs
in 5%-15% of patients after myeloablative allogeneic
hematopoietic stem cell transplantation (HSCT).
VOD is thought to result from conditioning-related
injury to hepatic sinusoidal endothelium and hepato-
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6/j.bbmt.2010.02.016related to allogenicity [1]. Although clinical risk factors
for VOD are well established, precise prediction of
VOD in individuals remains elusive.
In previous work, we demonstrated an increased
frequency of VOD after sirolimus-based graft-versus-
host disease (GVHD) prophylaxis (relative risk [RR],
1.55, P 5 .33 without concomitant methotrexate
[MTX]; RR, 2.35, P 5 .005 with concomitant MTX)
[2]. Sirolimus may act as an endothelial toxin or may
prevent endothelial repair after conditioning-related
or mechanical injury. It is commonly used to coat endo-
vascular stents to prevent restenosis [3] and has been as-
sociated with another endothelial injury syndrome,
thrombotic microangiopathy, after transplantation [4].
We hypothesized that the occurrence of VOD can
be predicted by measuring biomarkers of endothelial
injury, particularly in patients receiving sirolimus
therapy.
METHODS
We performed a retrospective analysis of bio-
markers of endothelial injury using banked plasma and
serum samples collected weekly in the peritransplanta-
tion period, with clinical VOD as the outcome of inter-
est. We selected 4 biomarkers—von Willebrand factor
(vWF), thrombomodulin, soluble intracellular adhesion
molecule-1 (sICAM-1), and E-selectin—based on
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sion pattern, and ability to be measured in stored plasma
or serum. The biomarkers were measured using
commercially available ELISA kits (vWF: American
Diagnostica, Greenwich, CT; thrombomodulin: Diag-
nostica Stago, Parsippany, NJ; sICAM-1 and E-selectin:
R&D Systems, Minneapolis, MN). vWF and thrombo-
modulin were assayed in plasma, and sICAM-1 and E-
selectin were assayed in serum.
All patients in the study group underwent myeloa-
blative HSCT using cyclophosphamide and total body
irradiation, as described previously [5]. In brief, cyclo-
phosphamide (1800 mg/m2 on days 25 and 24) was
administered, followed by total body irradiation at
14.0 Gy, delivered in 7 fractions at a dose rate of 10
cGy/min. Lead blocks were used to compensate for
lung absorption. Tacrolimus was administered at
0.02 mg/kg/day i.v. by continuous infusion beginning
on day 23, with a target serum concentration of 5-10
ng/mL. Sirolimus was administered as a 12-mg oral
loading dose on day -3, followed by a 4-mg/day single
dose, with a target serum concentration of 3-12 ng/mL
as assessed by high-performance liquid chromatogra-
phy. Recipients of matched related and matched unre-
lated grafts were included.
Patients were selected to represent 2 GVHD pro-
phylaxis groups: sirolimus/tacrolimus (SIR1) and ta-
crolimus/MTX (SIR-) with or without VOD
(VOD1/VOD-). A sufficient number of patients were
randomly selected from our database to ensure the
availability of least 10 samples for assay at each of 3
time points (days -1, 17, and 114); however, not all
patients in groups other than the SIR1VOD1 refer-
ence group had serum and plasma measurements at
each time point. Assays were performed before the
clinical development of VOD. VOD was diagnosed
based on the Baltimore criteria [6], with diagnosis con-
firmed by Doppler ultrasonography and/or liver bi-
opsy with wedged hepatic venous pressure gradient
measurement.Statistical Analysis
All assays were performed in duplicate, and the
results presented here are the mean of 2 assays. The
2-sided exact Wilcoxon rank-sum test was used for
comparison of continuous variables, and the 2-sided
Fisher exact test was used for comparison of categori-
cal variables. All biomarkers were first evaluated at
each time point. To establish a cutoff value for predic-
tive biomarkers, analysis of the receiver operator char-
acteristic (ROC) curve was performed at each time
point. To assess whether the cutoff value determined
in the ROC analysis predicted the occurrence of
VOD in the presence of other prognostic factors, exact
logistic regression analysis was performed at each time
point, adjusting for age, recipient–donor sex mis-match, and donor type. In addition, to test for a group
difference (ie, VOD1 vs VOD-) over time, a mixed
model for repeated measures was explored for each
biomarker using PROC MIXED in SAS version 9.2
(SAS Institute, Cary, NC). The level of each bio-
marker was log-transformed for modeling. All tests
were 2-sided. Testing for multiple biomarkers was
not adjusted for in the level of significance.RESULTS
Table 1 summarizes characteristics of the study pa-
tients. Significant intragroup differences in baseline
characteristics can be seen, with SIR1 patients engraft-
ing earlier than SIR- patients (14 days vs 16 days; P
\.01) and SIR1VOD1 patients being more likely to
receive an unrelated donor graft and to experience de-
layed platelet recovery. Only 2 patients (1 SIR1VOD1
and 1 SIR1VOD-) were exposed to gentuzumab ozo-
gomycin before HSCT. A total of 61 patients were
needed for the analysis to ensure the availability of
10 samples at each of the 3 analysis time points; how-
ever, in the SIR-VOD1 group, only 9 patients with
banked samples were ultimately identified. In the
SIR1VOD1 group, all 10 patients had samples at all
time points. The median time to development of
VOD was 17 days (range, 11-28 days) in the SIR1
group and 21 days (range, 10-40 days) in the SIR-
group (P 5 .35).
Comparison of Biomarkers
Significant differences in biomarker levels were de-
tected between SIR1 patients with VOD and those
without VOD. vWF, thrombomodulin, and sICAM-
1 levels were significantly elevated in VOD1 patients
compared with VOD- patients on days -1, 17, and
114 (Table 2 and Figure 1). E-selectin level was signif-
icantly elevated only on day17 (P5 .007). A repeated-
measures analysis performed for each predictive
biomarker found that each was significantly associated
with the occurrence of VOD when measured over time
(vWF, P 5 .003 mU/mL; thrombomodulin, P 5 .002
ng/mL; sICAM1, P 5 .004 ng/mL).
In contrast, biomarker levels did not differ signifi-
cantly between the SIR-VOD1 and SIR-VOD- groups
at any of the time points tested (Figure 1), except for
thrombomodulin level on day 17 (median, 46 vs 16;
P 5 .0003) and day 114 (median, 43 vs 21.5; P 5
.02). This difference was not seen on the repeated-
measures analysis, at least in partly because of the small
sample size. Even though the significant differences in
thrombomodulin level were seen between the
SIR-VOD1 and SIR-VOD- groups, the thrombomo-
dulin level in the SIR-VOD1 group was much lower
than that in the SIR1VOD1 group (median, 227.5;
P\.001).
Table 1. Clinical Characteristics of Patients Analyzed
SIR+VOD+ SIR+VOD- P SIR2VOD+ SIR-VOD- P
Sample size 12 26 9 14
Age, years, median (range) 45 (19-59) 42.5 (29-56) .85 34 (19-51) 48.5 (31-58) .03
Males sex, n (%) 9 (75) 8 (31) .02 33 79 .006
Matched related donor, n (%) 2 (17) 22 (85) <.001 33 64 <.001
Previous transplantation, n (%) 1 (8) 0 .32 0 0 1
Disease, n (%) NS NS
Acute myelogenous leukemia 4 (33) 9 (35) 5 (56) 6 (43)
Acute lymphoblastic leukemia 3 (25) 2 (8) 3 (33) 5 (36)
Chronic lymphocytic leukemia/small
lymphocytic leukemia/prolymphocytic leukemia
0 0 0 1 (7)
Chronic myelogenous leukemia 0 8 (31) 0 1 (7)
Myelodysplastic syndrome 2 (17) 2 (8) 0 1 (7)
Multiple myeloma 0 1 (4) 0 0
Myeloproliferative disease 1 (8) 1 (4) 0 0
Non-Hodgkin lymphoma 2 (17) 3 (12) 1 (11) 0
Time from diagnosis to transplant, months, median (range) 5.7 (3.2-26.2) 4.9 (2.1-31.6) .94 7.3 (2.0-34.3) 4.5 (2.7-17.1) .25
Time to neutrophil recovery, days, median (range) 14 (13-20) 13 (10-21) .13 17.5 (13-27) 16 (13-20) .44
Time to platelet recovery, days, median (range) 29 (14-138) 15 (8-39) .007 20 (15-102) 18 (14-26) .33
Grade II-IV acute GVHD, n (%) 3 (27) 8 (32) 1 5 (63) 6 (43) .66
NS indicates not significant.; SIR+, sirolimus/tacrolimus; SIR2, tacrolimus/methotrexate; VOD+, with veno-occlusive disease; VOD2, without veno-
occlusive disease; GVHD, graft-versus-host disease
1182 Biol Blood Marrow Transplant 16:1180-1185, 2010C. Cutler et al.Among patients without VOD, no differences in
biomarker levels were detected between SIR1 and
SIR- patients. This indicates that in the absence of
VOD, biomarkers of endothelial injury are not ele-
vated even when sirolimus is administered.Analysis of Receiver Operator Characteristic
Curves
A receiver operating characteristic (ROC) analysis
of SIR1 patients found that a vWF level $1200 mU/
mL was 100% sensitive and 90% specific for the devel-
opment of VOD when measured on day -1 (area under
the curve [AUC]50.99). At day17, a vWF level$1400
mU/mL was 100% sensitive and specific for the devel-
opment of VOD (AUC 5 1). A thrombomodulin level
$80 ng/mL on day -1 was 70% sensitive and 90% spe-
cific (AUC5 0.78), whereas a level$100 ng/mL by day
17 was 100% sensitive and 100% specific for the devel-
opment of VOD (AUC 5 1). Because each individual
biomarker was very predictive, the simultaneous useTable 2. Summary of Biomarkers in Patients Receiving Sirolimus T
SIR+VOD+
Time n Media
Day -1 Thrombomodulin (ng/mL) 10 94.5 (3
VWF (mU/mL) 10 1740 (1
E-selectin (ng/mL) 10 21 (6
sICAM1 (ng/mL) 10 585 (2
Day +7 Thrombomodulin (ng/mL) 10 227.5 (1
VWF (mU/mL) 10 1797 (1
E-selectin (ng/mL) 10 45.5 (1
sICAM1 (ng/mL) 10 1571 (4
Day +14 Thrombomodulin (ng/mL) 10 197.5 (9
VWF (mU/mL) 10 1774 (1
E-selectin (ng/mL) 10 39.5 (1
sICAM1 (ng/mL) 10 1055 (4
SIR+ indicates sirolimus/tacrolimus; SIR2, tacrolimus/methotrexate; VOD+,
sICAM1, soluble intercellular adhesion molecule-1; VWF, von Willebrand factof these 2 biomarkers did not add to the predictive
capability of these assays compared with vWF alone
(AUC 5 0.99 at day 21 and 1 at day 17). sICAM1
also was useful for the prediction of VOD; a level
$500 ng/mL on day -1, was 80% sensitive and 100%
specific for VOD (AUC 5 0.88), whereas on day 17,
a level$400 ng/ml was 100% sensitive and 90% specific
for VOD (AUC5 0.99). The simultaneous use of these
2 biomarkers did not add to the predictive capability of
these assays.
In the SIR- patients, a thrombomodulin level $35
ng/mL on day 17 was 100% sensitive and 100% spe-
cific for VOD (AUC5 1), whereas a vWF level$1200
ng/mL on day 17 was 100% sensitive and 70% spe-
cific for VOD (AUC5 0.72). But, because of the sam-
ple size constraints and the lack of reproducibility in
repeated-measures analyses, these results must be in-
terpreted with caution.
To investigate whether the proposed cutoff values
are independently predictive of VOD in the presence
of other risk factors, we performed multivariate exactherapy
SIR+VOD-
n (range) n Median (range) P
7-180) 10 57 (36-99) .035
136-1967) 10 581 (378-1230) .000022
-76) 10 38.5 (15-111) .17
35-1585) 10 273 (195-339) .0026
19-398) 10 29 (15-64) .000011
507-1827) 10 934.5 (441-1338) .000011
5-81) 10 20.5 (9-34) .0067
31-4321) 10 249 (180-438) .000022
5-272) 10 51 (26-126) .000022
267-1949) 10 1198 (745-1771) .0039
4-78) 9 26 (10-87) .13
81-2515) 9 386 (274-614) .00065
with veno-occlusive disease; VOD2, without veno-occlusive disease;
or.
Figure 1. Biomarker levels stratified by sirolimus exposure and VOD outcome. Line plots of biomarker levels and time from transplantation, stratified
into 4 clinical groups. Confidence intervals represent interquartile ranges.
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nostic factors as age, recipient–donor sex mismatch,
and donor type. Because of sample size constraints,
we contructed 2 models, one with donor type and bio-
marker and the other with age, recipient–donor sex
mismatch, and biomarker; both models used VOD as
the outcome of interest. In the first model, the odds
of VOD occurrence at day 17 in patients with
a vWF level $1400 mU/mL or a thrombomodulin
level $100 ng/mL was 5.65 (P 5 .004). For sICAM1,
the odds of VOD occurrence in patients with a day17
sICAM1 level $400 ng/mL was 4.45 (P 5 .036).
Results of the regression analysis are presented in
Table 3.DISCUSSION
Numerous previous attempts have been made to
identify predictive markers for VOD. In the presentTable 3. Summary of Logistic Regression Models for the Occurren
Time Biomarker OR (95% C
Day -1 vWF $1200 mU/mL 4.22 (1.41-
Day +7 vWF $1400 mU/mL 5.65 (1.74-
Thrombomodulin $100 ng/mL 5.65 (1.74-
sICAM1 $400 ng/mL 4.45 (1.10-
*VOD indicates veno-occlusive disease. Adjusting for donor type only.
†Adjusting for age and recipient–donor sex mismatch.study, we have identified markers of endothelial injury
that can predict the occurrence of VOD in patients
treated with sirolimus. Most previous studies focused
on parameters of hemostasis and coagulation, because
one of the prominent clinical features of VOD is mi-
crothrombus formation in the hepatic sinusoid. Sev-
eral studies have demonstrated changes in hemostatic
parameters at the time of VOD diagnosis, with ele-
vated plasminogen activator inhibitor-1 (PAI-1) level
the most common marker at the time of (but not be-
fore) the diagnosis of VOD [7,8]. PAI-1 has been
shown to have both diagnostic and prognostic value
in VOD [9]. We were unable to measure PAI-1 be-
cause we had no platelet-poor plasma cryopreserved
for assay. Gerecitano et al. [10] suggested that homo-
cysteine and prothrombin fragments 1 and 2 could
predict VOD occurrence with modest sensitivity, and
Scrobohaci et al. [11] found an association between
low baseline levels of factor VII and protein C with in-
creased risk for VOD. Other prospective studies foundce of VOD
I)* P* OR (95% CI)† P†
N) .009 2.57 (1.27-N) .009
N) .004 2.35 (1.23-N) .01
N) .004 2.35 (1.23-N) .01
N) .036 3.04 (1.25-N) .01
1184 Biol Blood Marrow Transplant 16:1180-1185, 2010C. Cutler et al.a decreased protein C level before the onset of VOD
[12-14]; however, in many cases, the protein C level
was diminished even before conditioning began,
suggesting that a low protein C level is a risk factor
for VOD. Similarly, impaired vWF cleaving protease
activity assessed before conditioning also may be
a risk factor for VOD [15].
Several groups have attempted to use endothelial
markers to predict VOD. Most were not able to
demonstrate the utility of the same markers that we
identified (vWF [11,16], thrombomodulin [17], and
E-selectin and sICAM-1 [18]) in predicting VOD.
Of note, none of these studies included patients who
had received sirolimus therapy.
The primary mechanism of injury in VOD is
thought to be conditioning-related injury to the he-
patic sinusoidal endothelium. The mechanism of in-
jury in sirolimus-exposed patients may be more
complicated, however. Conditioning-related injury
may be potentiated by sirolimus (or a combination of
sirolimus and tacrolimus), because sirolimus may ac-
celerate the senescence of hepatic endothelial cells af-
ter conditioning-related injury [19]. The healing
process after conditioning-related injury may be al-
tered as well. During recovery after VOD, excess vas-
cular endothelial growth factor may be released by the
hepatic endothelium to promote healing and endothe-
lial recovery [20]. Sirolimus may reduce vascular endo-
thelial growth factor levels, hindering repair in this
scenario [21]. Finally, the possibility exists that the
pathogenesis of VOD is multifactorial, and that only
a subset of patients sustain endothelial injury as the
primary mechanism, with sirolimus accentuating this
injury. This may explain why previous attempts to
identify endothelial markers of injury have not been
more fruitful.
In summary, we have demonstrate that VOD can
be predicted as early as the time of stem cell infusion
using markers of endothelial injury in patients receiv-
ing sirolimus. Our findings suggest that endothelial in-
jury predates clinical VOD by at least several days to as
much as weeks. The high sensitivity and specificity of
these assays make them useful for real-time clinical
testing and early clinical intervention. Using these
markers, specific strategies for preemptive therapy
(with agents that target endothelial injury [22,23]) in
these patients should be explored, which in turn
could improve outcomes in this disease. We plan on
validating this analysis with a prospective evaluation
of these biomarkers in the future.ACKNOWLEDGMENTS
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